Donald Trump survived his corona infection surprisingly quickly at the beginning of October. He attributes his recovery to a “cure” that he discovered by chance and that should soon be available to everyone. At least a first step has now been taken. US President Donald Trump praised the drug in the highest tones – the antibody cocktail for the treatment of Covid-19 has now received emergency approval in the USA. The US Food and Drug Administration (FDA) issued them to biotech company Regeneron on Saturday. This allows the cocktail with two antibodies to be used to treat patients aged twelve and over who are at risk of developing severe Covid 19 symptoms. Patients who are in the hospital or need oxygen should not be allowed to have the drug. The FDA approved after a clinical trial of 799 adults with mild to moderate Covid-19 symptoms who were out of the hospital.
Alleged cure discovered Trump calls his infection “God’s blessing”
According to the New York Times, Regeneron received more than $ 500 million from the US government to develop the drug. The government will provide the first 300,000 doses free of charge, but patients may have to pay health care facilities to have the drug administered, the drug maker said in a statement. The antibody cocktail is supposed to prevent the virus from entering the cell. According to the company, the treatment leads to a reduction in the viral load, i.e. the amount of detectable viruses, and a faster resolution of symptoms. The subjects who benefited most from the study were those whose immune systems had not yet produced their own antibodies against the virus. The antibodies are directed against two regions of the spike protein on the surface of the Sars-CoV-2 virus. After his recovery from Covid-19, Trump advertised the treatment of the disease with Regeneron’s antibody cocktail in October. The drug is not a treatment method, but a “cure” and a “miracle” that will soon be available to everyone, he had promised.
Online-PR: ... unsere digitale Pressearbeit im Internet hilft weiter...